FDA Compliance for Peptide Therapy and BPC 157 Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The biggest peptide story of 2026 may not be a new study. It may be the FDA review calendar. BPC 157, TB 500, MOTS c, Semax, and other peptides are headed into FDA advisory review Is BPC 157 Banned? Oral vs. Injectable Forms Explained